CD38 and nephrotic syndrome: Only one study used obinutuzumab (single dose 1,000 mg 1.73m2) in nephrotic syndrome in combination with sequential administration of the anti-CD38 (plasma cell) monoclonal antibody daratumumab (1,000 mg 1.73m2) after 14 days (55).